5.92
+0.08(+1.37%)
Currency In USD
Previous Close | 5.84 |
Open | 5.84 |
Day High | 6.05 |
Day Low | 5.72 |
52-Week High | 16.74 |
52-Week Low | 4.25 |
Volume | 925,830 |
Average Volume | 1.18M |
Market Cap | 908.64M |
PE | -8.46 |
EPS | -0.7 |
Moving Average 50 Days | 9.23 |
Moving Average 200 Days | 9.84 |
Change | 0.08 |
If you invested $1000 in Wave Life Sciences Ltd. (WVE) since IPO date, it would be worth $370 as of April 19, 2025 at a share price of $5.92. Whereas If you bought $1000 worth of Wave Life Sciences Ltd. (WVE) shares 5 years ago, it would be worth $726.38 as of April 19, 2025 at a share price of $5.92.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531
GlobeNewswire Inc.
Mar 26, 2025 11:30 AM GMT
Statistically significant and clinically meaningful improvement of 3.8 seconds in Time-to-Rise vs. natural history with largest effect observed relative to any approved dystrophin restoration therapy at 48 weeks; additional functional benefits observ
Wave Life Sciences Fourth Quarter and Full Year 2024 Financial Results Scheduled for March 4, 2025
GlobeNewswire Inc.
Feb 25, 2025 1:30 PM GMT
CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conf
Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity
GlobeNewswire Inc.
Feb 06, 2025 1:30 PM GMT
WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new approach for healthy, sustainable weight loss (fat loss with muscle preservation) Proof-of-concept clinical data from INLIGHT are e
Data not available